Analytical methods and arrays for use in the same

An in vitro method for measuring biomarkers for human skin sensitizers comprising the steps of:

• a) exposing a population of dendritic cells or a population of dendritic-like cells to a test agent;
• and
• b) measuring in the exposed cells of step a) the expression of nucleic acid molecules encoding each of the following 51 biomarkers for human skin sensitizers:
• histone cluster 1, H2bm (HIST1H2BM);
• histone cluster 1, H4b (HIST1H4B);
• histone cluster 1, Hid (HIST1H1D);
• phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS);
• histone cluster 1, H4d (HIST1H4D);
• histone cluster 1, H2a1/histone cluster 1, H2bn (HIST1H2AL/HIST1H2BN);
• polo-like kinase 1 (PLK1);
• phosphoglycerate dehydrogenase (PHGDH);
• minichromosome maintenance complex component 2 (MCM2);
• minichromosome maintenance complex component 7 (MCM7);
• CD53;
• kinesin family member C1 (KIFC1);
• WEE1 G2 checkpoint kinase (WEE1);
• thymopoietin (TMPO);
• minichromosome maintenance complex component 4 (MCM4);
• proline/serine-rich coiled-coil 1 (PSRC1);
• ring finger protein 149 (RNF149);
• minichromosome maintenance complex component 6 (MCM6);
• minichromosome maintenance complex component 5 (MCM5);
• Fanconi anemia complementation group A (FANCA);
• carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD);
• MRT4 homolog, ribosome maturation factor (MRTO4);
• target of EGR1, member 1 (TOE1);
• cell division cycle 20 (CDC20);
• peptidase M20 domain containing 2 (PM20D2);
• NmrA-like family domain containing 1 pseudogene (LOC344887);
• uracil DNA glycosylase (UNG);
• cyclin-dependent kinase inhibitor 1A (CDKN1A);
• histone cluster 1, H2bf (HIST1H2BF);
• histone cluster 1, H1b (HIST1H1B);
• jade family PHD finger 1 (JADE1);
• KIAA0125;
• cholinergic receptor, nicotinic alpha 5 (CHRNA5);
• chromatin assembly factor 1, subunit B (p60)/MORC family CW-type zinc finger 3 (CHAF1B/MORC3);
• sel-1 suppressor of lin-12-like 3 (SEL1L3);
• structure specific recognition protein 1 (SSRP1);
• forkhead box Ml (FOXM1);
• lamin B1 (LMNB1);
• histone cluster 1, H2ak (HIST1H2AK);
• centromere protein A (CENPA);
• non-SMC condensin I complex subunit H (NCAPH);
• histone cluster 1, H2bb (HIST1H2BB);
• ATPase, H+ transporting, lysosomal 56/58 kDa, V1 subunit B2 (ATP6V1B2);
• TNF receptor-associated protein 1 (TRAP1);
• phosphoribosylformylglycinamidine synthase (PFAS);
• transmembrane protein 97 (TMEM97);
• 24-dehydrocholesterol reductase (DHCR24);
• ferritin, heavy polypeptide 1 (FTH1);
• histone cluster 1, H2ae (HIST1H2AE);
• NAD(P)H dehydrogenase, quinone 1 (NQO1);
• and CD44,
• wherein step b) is performed using an array comprising binding moieties, wherein the binding moieties consist of different binding moieties each capable of binding selectively to a nucleic acid molecule encoding one of the 51 biomarkers for human skin sensitizers.